Skip to main content
Terug
Watch Compare

AYTU BIOPHARMA, INC

Datakwaliteit: 100%
AYTU
Nasdaq Manufacturing Chemicals
€ 2,55
▼ € 0,02 (-0,78%)
Marktkapitalisatie: 27,58 M
Prijs
€ 2,57
Marktkapitalisatie
27,58 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue grew 0,28% annually over 5 years — modest growth
Negative free cash flow of -840.000,0
Revenue growth is decelerating — 1Y growth trails 5Y average by 18,33%
Capital efficient — spends only 0,39% of revenue on capex

Groei

Revenue Growth (5Y)
0,28%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-18,05%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-130,81%
Onder sectorgemiddelde (-53,47%)
ROIC-11,88%
Net Margin-39,02%
Op. Margin-13,85%

Veiligheid

Debt / Equity
0,70
Boven sectorgemiddelde (0,30)
Current Ratio1,16
Interest Coverage-3,21

Waardering

PE (TTM|2027)
-1,13 | 15,12
Boven sectorgemiddelde (-1,48)
P/B Ratio1,94
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,1 -1,5
P/B 1,9 1,6
ROE % -130,8 -53,5
Net Margin % -39,0 -41,5
Rev Growth 5Y % 0,3 1,8
D/E 0,7 0,3

Koersdoel Analisten

3 analisten
Buy
Huidig
€ 2,55
+279.1%
Koersdoel
€ 9,67
€ 7,00
€ 8,00
€ 14,00
Vooruitzicht
Forward K/W 15,00
Forward WPA € 0,17
Omzet Sch. 81,40 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 € 0,17
€ 0,04 – € 0,30
 81,40 M 2
FY2026 -€ 1,47
-€ 1,59 – -€ 1,34
 57,06 M 2

Winstverassingen

Laatste 6 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,50 -€ 0,23 +52,9%
Q32025 -€ 0,20 -€ 0,09 +52,1%
Q22025 -€ 0,06 -€ 0,08 -27,3%
2026-Q2 -€ 0,20 -€ 0,81 -305,0%
2026-Q1 -€ 0,62 -€ 0,08 +87,0%
Q12025 -€ 0,17 € 0,21 +223,5%

ETFs Holding This Stock

PRCGX PRCGX
0,08% weight
BOSVX BOSVX
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -18,05% Revenue Growth (3Y) -21,38%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 0,28% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 62,64 M Net Income (TTM) -24,44 M
ROE -130,81% ROA -19,79%
Gross Margin 66,84% Operating Margin -13,85%
Net Margin -39,02% Free Cash Flow (TTM) -840.000,0
ROIC -11,88% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,70 Current Ratio 1,16
Interest Coverage -3,21 Asset Turnover 0,51
Working Capital 10,68 M Tangible Book Value -29,38 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,13 Forward P/E N/A
P/B Ratio 1,94 P/S Ratio 0,44
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -3,05%
Market Cap 27,58 M Enterprise Value 7,56 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share 5,84
FCF / Share -0,08 OCF / Share -0,06
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,39% FCF Conversion 3,44%
SBC-Adj. FCF -1,55 M Growth Momentum -18,33

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 66,38 M 81,00 M 107,40 M 96,67 M 65,63 M
Net Income -13,56 M -15,84 M -17,05 M -110,17 M -58,29 M
EPS (Diluted) — — -5,11 -3,75 —
Gross Profit 45,83 M 54,59 M 66,63 M 52,28 M 29,20 M
Operating Income -7,83 M -5,25 M -17,07 M -111,56 M -58,87 M
EBITDA — — — — —
R&D Expenses 1,33 M 2,79 M 4,10 M 14,44 M 5,62 M
SG&A Expenses — — — — —
D&A — 8,27 M 8,82 M 10,25 M 9,20 M
Interest Expense 3,70 M 4,79 M — 900.000,0 —
Income Tax 437.000,0 1,77 M 0,0 -110.000,0 259.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 124,18 M 118,10 M 136,46 M 137,62 M 265,67 M
Total Liabilities — — 97,11 M 91,53 M 128,10 M
Shareholders' Equity 18,97 M 27,72 M 39,36 M 46,09 M 137,57 M
Total Debt 10,90 M 13,27 M 16,56 M 15,00 M —
Cash & Equivalents 30,95 M 20,01 M 22,99 M 19,36 M 49,65 M
Current Assets 79,18 M — 72,83 M 59,93 M 105,23 M
Current Liabilities 63,06 M 62,23 M 69,02 M 64,44 M 109,44 M